Regeneron (REGN)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-02 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: REGENERON PHARMACEUTICALS, INC. (REGN) CIK: 0000872589 --- Reporting Owner --- Name: Guarini Kathryn CIK: 0001992352 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-09-02 | Code: M (Exercise of derivative) Shares: +400 | Price: $719.37 Total Value: $287,748.00 Shares Owned After: 1,003 | Ownership: D (Direct) Footnotes: [F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. [Transaction #2] Security: Common Stock Date: 2026-09-02 | Code: S (Open market sale) Shares: -400 | Price: $850.00 Total Value: $340,000.00 Shares Owned After: 603 | Ownership: D (Direct) Footnotes: [F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. --- Derivative Transactions --- [Transaction #1] Security: Non-Qualified Stock Option (right to buy) Date: 2026-09-02 | Code: M (Exercise of derivative) Shares: -400 | Price: $0.00 Exercise Price: $719.37 Exercisable: N/A | Expires: 2035-01-02 Shares Owned After: 1,158 | Ownership: D (Direct) Footnotes: [F1] Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. [F2] On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. --- Footnotes (Complete Index) --- F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. F2: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. --- Signature --- /s/ /s/ Kathryn Guarini (2026-09-03)